Read our latest news, and find more about us and our portfolio companies.
Please visit our investor relations section to review the latest information
Arix
18th December 2020
Completion of sale of VelosBio
Portfolio Company
3rd December 2020
Artios and Merck KGaA announce global strategic collaboration
5th November 2020
VelosBio to be acquired by Merck for $2.75 billion
9th June 2020
Arix to present at Proactive One2One Biotech Forum
8th June 2020
Arix announces strategic and operational update
3rd June 2020
Arix to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
20th May 2020
Amplyx closes $53 million Series C extension
12th May 2020
Notice of Annual General Meeting
15th April 2020
Investment team changes
12th March 2020
Imara prices Nasdaq IPO
9th March 2020
Arix names Dr Roberto Iacone as Entrepreneur in Residence
27th January 2020
Arix co-founds Quench Bio with Series A financing
17th January 2020
Iterum announces $52 million private placement
3rd October 2019
Arix 2019 Capital Markets Day
30th September 2019
Arix co-leads EUR 20 million Series A investment round in STipe Therapeutics
13th September 2019
Imara announces confidential submission of draft registration statement for proposed US IPO
28th August 2019
Interim results for the six months ended 30 June 2019
16th April 2019
Arix Bioscience plc Autolus announces closing of public offering
11th April 2019
Autolus announces pricing of public offering
2nd April 2019
Aura completes $40 million Series D financing
28th March 2019
Annual Results for the year ended 31 December 2018
Arix Bioscience plc Board changes
18th March 2019
Arix co-leads $63 million Series B investment round for Imara
19th February 2019
Management and Board changes
14th February 2019
Harpoon closes initial public offering
8th February 2019
Harpoon prices Nasdaq IPO
29th January 2019
Update on Harpoon proposed IPO in the United States
28th December 2018
Harpoon announces proposed public offering in the United States
11th December 2018
Arix appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)
3rd December 2018
Autolus presents initial AUTO3 data at ASH
10th October 2018
Update on LogicBio proposed initial public offering in the United States
1st October 2018
Co-leads $58 million Series A investment round for VelosBio
26th September 2018
LogicBio files registration for proposed IPO in the US
13th September 2018
Arix Bioscience Plc announces Board changes
4th September 2018
Changes announced to executive team to accelerate growth and strategy
10th August 2018
Artios completes £65m Series B investment round
6th August 2018
Arix Bioscience announces first VIPE investment
30th July 2018
Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2018
26th July 2018
Autolus announces closing of IPO
8th June 2018
Update on Autolus proposed initial public offering in the United States
31st May 2018
Arix Bioscience forms strategic collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to foster new companies in cancer and infectious diseases
Lord John Hutton steps down from Board of Directors of Arix Bioscience plc
30th May 2018
Iterum Therapeutics plc Closes Initial Public Offering
25th May 2018
Iterum Therapeutics plc Prices Initial Public Offering
23rd April 2018
Annual Results 2017
5th April 2018
Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018
19th February 2018
Arix Bioscience and Fosun International sign strategic agreement to develop and commercialise new clinical therapies for patients
21st December 2017
Arix Bioscience co-leads $30 million financing for Aura Biosciences
25th May 2017
Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics
19th May 2017
Arix Bioscience leads $65 million Series B investment round for Iterum
28th April 2017
Maiden Annual Results 2016
21st September 2016
Arix supports Artios Pharma, a new biotech company focused on DNA damage response
25th July 2016
ARIX BIOSCIENCE SUPPORTS DEPIXUS, AN EARLY-STAGE COMPANY FOCUSED ON NUCLEIC ACID SEQUENCING & EPIGENETIC ANALYSIS
20th June 2016
ARIX BIOSCIENCE SUPPORTS INNOVATIVE RESPIRATORY DRUG COMPANY VERONA PHARMA PLC
13th June 2016
ARIX BIOSCIENCE SUPPORTS OPTIKIRA, A COMPANY DEVELOPING DRUGS TO FIGHT BLINDNESS
18th April 2016
ARIX BIOSCIENCE HAS MADE $25 MILLION COMMITMENT TO LEADING THERAPEUTICS RESEARCH ACCELERATOR, BIOMOTIV
3rd March 2016
ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS